Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35354
Title: | Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. | Authors: | Torres J.;Feagan B.G.;Chande N.;MacDonald J.K.;Parker C.E.;East J.E.;Boyapati R.K. | Monash Health Department(s): | Gastroenterology and Hepatology | Institution: | (East) Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, Experimental Medicine Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom (Boyapati) Department of Gastroenterology, Monash Health, Melbourne, VIC, Australia (Torres) Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States (Torres) Hospital Beatriz Angelo, Gastroenterology Division, Loures, Portugal (Parker, Feagan) Robarts Clinical Trials Inc., London, ON, Canada (MacDonald, Chande, Feagan) Cochrane IBD Group, University of Western Ontario, London, ON, Canada (Chande, Feagan) Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, ON, Canada (Feagan) Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON N6A 5B6, Canada | Issue Date: | 6-May-2020 | Copyright year: | 2019 | Publisher: | Oxford University Press | Place of publication: | United States | Publication information: | Inflammatory Bowel Diseases. 25 (3) (pp 472-478), 2019. Date of Publication: 01 Mar 2019. | Journal: | Inflammatory Bowel Diseases | Abstract: | A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.Copyright © 2018 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/ibd/izy268 | PubMed URL: | 30789982 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30789982] | ISSN: | 1078-0998 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35354 | Type: | Review | Subjects: | ulcerative colitis aminosalicylic acid corticosteroid mesalazine/ct mesalazine methylprednisolone olsalazine olsalazine/ct prednisone salazosulfapyridine remission Crohn Disease Activity Index diarrhea cancer susceptibility colon cancer Crohn disease drug efficacy drug safety inflammatory bowel disease interstitial nephritis pancreatitis pericarditis pleurisy Crohn disease |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.